Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors - LoRusso, P M; Gadgeel, S M; Wozniak, A; Barge, A J; Jones, H K; DelProposto, Z S; DeLuca, P A; Evelhoch, J L; Boerner, S A; Wheeler, C (Invest New Drugs, 2008)